Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia
| Status: | Archived |
|---|---|
| Conditions: | Pneumonia |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2010 |
| End Date: | June 2012 |
A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity
A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens
of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.
The study is a Phase 2, global, prospective, multi-dose, double-blind, double-dummy,
active-control, randomized, parallel-group, multicenter study of oral zabofloxacin HCl
(400mg) versus oral levofloxacin (500mg) in the treatment of adults with community-acquired
pneumonia of moderate severity.
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials